These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12564936)

  • 41. Explicit solvent dynamics and energetics of HIV-1 protease flap opening and closing.
    Sadiq SK; De Fabritiis G
    Proteins; 2010 Nov; 78(14):2873-85. PubMed ID: 20715057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Passive transport of C60 fullerenes through a lipid membrane: a molecular dynamics simulation study.
    Bedrov D; Smith GD; Davande H; Li L
    J Phys Chem B; 2008 Feb; 112(7):2078-84. PubMed ID: 18229908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Binding pathways of ligands to HIV-1 protease: coarse-grained and atomistic simulations.
    Chang CE; Trylska J; Tozzini V; McCammon JA
    Chem Biol Drug Des; 2007 Jan; 69(1):5-13. PubMed ID: 17313452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substrate binding mechanism of HIV-1 protease from explicit-solvent atomistic simulations.
    Pietrucci F; Marinelli F; Carloni P; Laio A
    J Am Chem Soc; 2009 Aug; 131(33):11811-8. PubMed ID: 19645490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of structural water molecule in HIV protease-inhibitor complexes: a QM/MM study.
    Suresh CH; Vargheese AM; Vijayalakshmi KP; Mohan N; Koga N
    J Comput Chem; 2008 Aug; 29(11):1840-9. PubMed ID: 18351589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling interactions between C₆₀ antiviral compounds and HIV protease.
    Al Garalleh H; Thamwattana N; Cox BJ; Hill JM
    Bull Math Biol; 2015 Jan; 77(1):184-201. PubMed ID: 25583353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Screening of new HIV inhibitors based on the database of traditional Chinese medicine].
    Gao WN; Li Y; Zhang R; Gao H; Xu WR; Li AX; Du QS; Zhang X; Wei DQ
    Yao Xue Xue Bao; 2006 Mar; 41(3):241-6. PubMed ID: 16758996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
    Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
    J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In silico drug screening approach for the design of magic bullets: a successful example with anti-HIV fullerene derivatized amino acids.
    Durdagi S; Supuran CT; Strom TA; Doostdar N; Kumar MK; Barron AR; Mavromoustakos T; Papadopoulos MG
    J Chem Inf Model; 2009 May; 49(5):1139-43. PubMed ID: 19371030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
    J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
    Perez MA; Fernandes PA; Ramos MJ
    J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations.
    Kurt N; Scott WR; Schiffer CA; Haliloglu T
    Proteins; 2003 May; 51(3):409-22. PubMed ID: 12696052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
    Durdagi S; Mavromoustakos T; Papadopoulos MG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region.
    Geller M; Miller M; Swanson SM; Maizel J
    Proteins; 1997 Feb; 27(2):195-203. PubMed ID: 9061783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.